Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Ovarian Neoplasms

  Free Subscription


Articles published in Ann Oncol

Retrieve available abstracts of 48 articles:
HTML format
Text format



Single Articles


    May 2017
  1. CONDORELLI R, Andre F
    Combining PI3K and PARP inhibitors for breast and ovarian cancer tratement.
    Ann Oncol. 2017 May 15. doi: 10.1093.
    PubMed     Text format    


  2. BAMIAS A, Gibbs E, Khoon Lee C, Davies L, et al
    Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial.
    Ann Oncol. 2017 May 8. doi: 10.1093.
    PubMed     Text format     Abstract available


  3. MONK BJ, Brady MF, Aghajanian C, Lankes HA, et al
    A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study.
    Ann Oncol. 2017;28:996-1004.
    PubMed     Text format     Abstract available


    April 2017
  4. RAY-COQUARD I, Lorusso D
    Immunotherapy and Epithelial Ovarian Cancer: a double-edged sword?
    Ann Oncol. 2017 Apr 3. doi: 10.1093.
    PubMed     Text format    


    March 2017
  5. POVEDA A, Del Campo JM, Ray-Coquard I, Alexandre J, et al
    Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer.
    Ann Oncol. 2017 Mar 20. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2017
  6. MONK BJ, Brady MF, Aghajanian C, Lankes HA, et al
    A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study.
    Ann Oncol. 2017 Feb 21. doi: 10.1093.
    PubMed     Text format     Abstract available


  7. KARAM A, Ledermann JA, Kim JW, Sehouli J, et al
    Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions.
    Ann Oncol. 2017 Feb 21. doi: 10.1093.
    PubMed     Text format     Abstract available


    January 2017
  8. MCGEE J, Bookman M, Harter P, Marth C, et al
    5th Ovarian Cancer Consensus Conference: Individualized Therapy and Patient Factors.
    Ann Oncol. 2017 Jan 24. pii: mdx010. doi: 10.1093.
    PubMed     Text format     Abstract available


    December 2016
  9. WILSON MK, Pujade-Lauraine E, Aoki D, Mirza MR, et al
    5th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recurrent Disease.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  10. LEARY AF, Quinn M, Fujiwara K, Coleman RL, et al
    5th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): Clinical trial design for rare ovarian tumours.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    November 2016
  11. MESNAGE SJ, Auguste A, Genestie C, Dunant A, et al
    Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC).
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  12. LIU JF, Moore KN, Birrer MJ, Berlin S, et al
    Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer.
    Ann Oncol. 2016;27:2124-2130.
    PubMed     Text format     Abstract available


  13. WEIDERPASS E, Botteri E
    Ovarian cancer mortality trends: which factors are involved?
    Ann Oncol. 2016;27:1977-1978.
    PubMed     Text format    


    September 2016
  14. MALVEZZI M, Carioli G, Rodriguez T, Negri E, et al
    Global trends and predictions in ovarian cancer mortality.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  15. LEDERMANN JA, Sessa C, Colombo N
    appendix 7: Ovarian cancer: eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Gynaecological-Malignancies).
    Ann Oncol. 2016;27.
    PubMed     Text format    


    August 2016
  16. BENTIVEGNA E, Gouy S, Maulard A, Pautier P, et al
    FERTILITY-SPARING SURGERY IN EPITHELIAL OVARIAN CANCER: A SYSTEMATIC REVIEW OF ONCOLOGICAL ISSUES.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    July 2016
  17. LINDEMANN K, Kristensen G, Mirza MR, Davies L, et al
    Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    June 2016
  18. RUSTIN GJ, Hall MR
    Is CA125 useful in monitoring patients with platinum resistant ovarian cancer?
    Ann Oncol. 2016.
    PubMed     Text format    


  19. MCNEISH IA
    Prognostic pathways in early stage ovarian cancer - can gene expression transcend histological subtype?
    Ann Oncol. 2016.
    PubMed     Text format    


  20. VOLGGER BM, Windbichler GH, Zeimet AG, Graf AH, et al
    LONG-TERM SIGNIFICANCE OF URINARY NEOPTERIN IN OVARIAN CANCER - A STUDY BY THE AUSTRIAN ASSOCIATION FOR GYNECOLOGIC ONCOLOGY (AGO).
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  21. TRILLSCH F, Mahner S, Hilpert F, Davies L, et al
    Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    May 2016
  22. CALURA E, Paracchini L, Fruscio R, Di Feo A, et al
    A prognostic regulatory pathway in stage I Epithelial Ovarian Cancer: new hints for the poor prognosis assessment.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    April 2016
  23. DI MAIO M, Perrone F
    Lessons from clinical trials on quality of life assessment in ovarian cancer trials.
    Ann Oncol. 2016.
    PubMed     Text format    


  24. POVEDA A, Romero I
    Advanced ovarian cancer: 20 years of ovarian cancer treatment.
    Ann Oncol. 2016;27 Suppl 1:i72-i73.
    PubMed     Text format    


  25. FRIEDLANDER M, Mercieca-Bebber RL, King MT
    Patient-reported outcomes (PRO) in ovarian cancer clinical trials-lost opportunities and lessons learned.
    Ann Oncol. 2016;27 Suppl 1:i66-i71.
    PubMed     Text format     Abstract available


  26. PUJADE-LAURAINE E, Combe P
    Recurrent ovarian cancer.
    Ann Oncol. 2016;27 Suppl 1:i63-i65.
    PubMed     Text format     Abstract available


  27. BOOKMAN MA
    Optimal primary therapy of ovarian cancer.
    Ann Oncol. 2016;27 Suppl 1:i58-i62.
    PubMed     Text format     Abstract available


  28. LEDERMANN JA
    PARP inhibitors in ovarian cancer.
    Ann Oncol. 2016;27 Suppl 1:i40-i44.
    PubMed     Text format     Abstract available


  29. KRZYSTYNIAK J, Ceppi L, Dizon DS, Birrer MJ, et al
    Epithelial ovarian cancer: the molecular genetics of epithelial ovarian cancer.
    Ann Oncol. 2016;27 Suppl 1:i4-i10.
    PubMed     Text format     Abstract available


  30. MONK BJ, Minion LE, Coleman RL
    Anti-angiogenic agents in ovarian cancer: past, present, and future.
    Ann Oncol. 2016;27 Suppl 1:i33-i39.
    PubMed     Text format     Abstract available


  31. MAHNER S, Trillsch F, Chi D, Harter P, et al
    Neoadjuvant chemotherapy in ovarian cancer revisited.
    Ann Oncol. 2016;27 Suppl 1:i30-i32.
    PubMed     Text format     Abstract available


  32. REYNERS AK, Broekman KE, Glaudemans AW, Brouwers AH, et al
    Molecular imaging in ovarian cancer.
    Ann Oncol. 2016;27 Suppl 1:i23-i29.
    PubMed     Text format     Abstract available


  33. COUKOS G, Tanyi J, Kandalaft LE
    Opportunities in immunotherapy of ovarian cancer.
    Ann Oncol. 2016;27 Suppl 1:i11-i15.
    PubMed     Text format     Abstract available


  34. KAYE SB
    Progress in the treatment of ovarian cancer-lessons from homologous recombination deficiency-the first 10 years.
    Ann Oncol. 2016;27 Suppl 1:i1-i3.
    PubMed     Text format     Abstract available


    March 2016
  35. MOSCHETTA M, George A, Kaye SB, Banerjee S, et al
    BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  36. FUJIWARA K, Monk BJ, Lhomme C, Coleman RL, et al
    Health-related Quality of Life in Women With Recurrent Ovarian Cancer Receiving Paclitaxel Plus Trebananib or Placebo (TRINOVA-1).
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  37. MATULONIS UA, Penson RT, Domchek SM, Kaufman B, et al
    Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multi-study analysis of response rates and safety.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    January 2016
  38. PETRILLO M, Zannoni G, Beltrame L, Martinelli E, et al
    Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neo-adjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    December 2015
  39. LORUSSO D, Scambia G, Pignata S, Sorio R, et al
    PROSPECTIVE PHASE II TRIAL OF TRABECTEDIN IN BRCA MUTATED AND/OR BRCAness PHENOTYPE RECURRENT OVARIAN CANCER PATIENTS: THE MITO 15 TRIAL.
    Ann Oncol. 2015.
    PubMed     Text format     Abstract available


    October 2015
  40. TEWARI KS, Java JJ, Eskander RN, Monk BJ, et al
    Early Initiation of Chemotherapy following Complete Resection of Advanced Ovarian Cancer Associated with Improved Survival: An NRG Oncology/Gynecologic Oncology Group Study.
    Ann Oncol. 2015.
    PubMed     Text format     Abstract available


    July 2015
  41. DIJKGRAAF EM, Santegoets SJ, Reyners AK, Goedemans R, et al
    A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-alpha 2b in patients with recurrent epithelial ovarian cancer.
    Ann Oncol. 2015.
    PubMed     Text format     Abstract available


    December 2014
  42. SCHOFFSKI P, Besse B, Gauler T, de Jonge MJ, et al
    Efficacy and safety of biweekly intravenous administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small cell and non-small cell l
    Ann Oncol. 2014.
    PubMed     Text format     Abstract available


    September 2014
  43. SELLE F, Sevin E, Ray-Coquard I, Mari V, et al
    A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma.
    Ann Oncol. 2014.
    PubMed     Text format     Abstract available


    July 2014
  44. MCNEISH IA, Ledermann JA, Webber L, James L, et al
    A randomised placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer.
    Ann Oncol. 2014.
    PubMed     Text format     Abstract available


    May 2014
  45. BALMANA J, Tung NM, Isakoff SJ, Grana B, et al
    Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors.
    Ann Oncol. 2014.
    PubMed     Text format     Abstract available


    April 2014
  46. PRAT J
    The results of conservative (fertility-sparing) treatment in borderline ovarian tumors vary depending on age and histological type.
    Ann Oncol. 2014.
    PubMed     Text format    


  47. UZAN C, Nikpayam M, Ribassin-Majed L, Gouy S, et al
    Influence of histological subtypes on the risk of an invasive recurrence in a large series of stage i borderline ovarian tumor including 191 conservative treatments.
    Ann Oncol. 2014.
    PubMed     Text format     Abstract available


    March 2014
  48. TRILLSCH F, Mahner S, Woelber L, Vettorazzi E, et al
    Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: Results from a subanalysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT Study.
    Ann Oncol. 2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: